<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00642694</url>
  </required_header>
  <id_info>
    <org_study_id>06-031R</org_study_id>
    <secondary_id>112006-017</secondary_id>
    <nct_id>NCT00642694</nct_id>
  </id_info>
  <brief_title>Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon</brief_title>
  <acronym>TAKEDA</acronym>
  <official_title>Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda Pharmaceuticals North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis I: Patients in the SSRI + ramelteon treatment group will achieve remission
      (defined as an IDS-C30 score of 11 or less) more quickly than those in the SSRI + placebo
      group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to assess the time to remission in depression with
      initial insomnia using the SSRI antidepressant escitalopram combined with ramelteon or
      placebo. Patients will be assessed at each visit for depressive symptoms and insomnia, using
      the 30-item Inventory of Depressive Symptoms, Clinician-Rated version (IDS-C30; Rush et al
      1986; Rush et al., 1996) as the primary outcome measure. The IDS self-report version will be
      used to assess self-reported changes in symptom severity. The 17 item Hamilton Rating Scale
      for Depression, (HRSD17; Hamilton, 1960) will also be administered, as it is the most
      commonly utilized depression symptom severity measure at this time.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrollment discontinued based on mutually agreed upon decision by PI and funding sponsor
  </why_stopped>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Remitters on IDS-C30 at Week 12</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Remission as defined by a score of &lt;12 on the Inventory of Depressive Symptomatology, Clinician-Rated version (IDS-C30) at Week 12; minimum possible score = 0, maximum possible score = 84; higher scores indicate worse symptom severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sleep Latency</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of minutes until fell asleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychosocial Measures i.e. SF Health Survey, QLESQ, Social Adjustment Scale Self Report, Work and Social Adjustment Scale, Work Productivity and Activity Impairment Questionaire, and the Patients Perception of Benefits of Care.</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Rating Scale for Depression 17-item</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escitalopram tablets (starting dose of 10 mg with a maximum dose of 20 mg daily) + Ramelteon (One 8 mg capsule at night)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Escitalopram tablets (starting dose of 10 mg with a maximum dose of 20 mg daily) + Matching Placebo (One capsule at night)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>Escitalopram 10 or 20mg qd based on symptoms at patient visit</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Lexapro (escitalopram)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramelteon</intervention_name>
    <description>Ramelteon 8 mg qd</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Rozerem (Ramelteon)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo qd</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability and willingness to provide written informed consent.

          -  Primary diagnosis of MDD with initial insomnia.

          -  Age 18-70.

          -  Screening HRSD17 score greater than or equal to 16 or CGI-S score of at least 4.

          -  Subjective report of difficulties with initial insomnia with a score of 2 or greater
             on the IDS-C30 item addressing this symptom (#1). Middle and late insomnia may also be
             present so long as initial insomnia is present.

        Exclusion Criteria:

          -  Presence of significant comorbid medical condition based on laboratory test, physician
             information, or evidence at examination; this includes severe sleep apnea, seizure
             disorder, or chronic obstructive pulmonary disease (COPD).

          -  Patient report or evidence (based on physical examination or laboratory tests) of
             significant medical abnormalities; this includes severe sleep apnea, seizure disorder,
             or COPD.

          -  Presence of other psychological disorders, including depression due to other comorbid
             conditions, currently suicidal or high suicide risk, current or past psychotic
             disorders of any type, bipolar disorder (I, II, or NOS), schizophrenia, or
             schizoaffective disorder, anorexia, bulimia, obsessive compulsive disorder, alcohol or
             substance abuse within the last 6 months, or patients with comorbid psychiatric
             conditions that are relative or absolute contraindications to the use of escitalopram
             or ramelteon.

          -  Concomitant (i.e. within 2 weeks; 4 weeks for fluoxetine or MAOIs) pharmacological or
             psychotherapeutic treatment including but not limited to anxiolytics, neuroleptics,
             mood stabilizers, sleep aids including over the counter melatonin, and/or other agents
             without proven antidepressant efficacy, cognitive behavioral therapy; current use of
             other medications that would be contraindicated with ramelteon or escitalopram,, as
             determined by the study doctor.

          -  Failure to respond to 2 adequate courses of SSRI class antidepressant in the current
             episode (as measured by the Antidepressant Treatment History Form).

          -  Hospitalization for mental illness within the past year.

          -  For women, currently pregnant, planning to become pregnant in the next year, or
             breastfeeding.

          -  Patient does not speak English. (Patient needs to be fluent in written and oral
             English because not all assessments are available and/or validated in languages other
             than English).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>752390-9119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.utsouthwestern.edu/utsw/home/.research/depression</url>
    <description>Mood Disorders Research Program and Clinic</description>
  </link>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2008</study_first_submitted>
  <study_first_submitted_qc>March 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2008</study_first_posted>
  <results_first_submitted>March 29, 2012</results_first_submitted>
  <results_first_submitted_qc>October 24, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 26, 2012</results_first_posted>
  <last_update_submitted>October 24, 2012</last_update_submitted>
  <last_update_submitted_qc>October 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Prabha Sunderajan</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>MDD</keyword>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Depression</keyword>
  <keyword>Initial Insomnia</keyword>
  <keyword>sleep</keyword>
  <keyword>difficulty sleeping</keyword>
  <keyword>down</keyword>
  <keyword>sad</keyword>
  <keyword>Major Depressive Disorder(MDD) and initial insomnia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Escitalopram + Ramelteon</title>
          <description>active augmentation</description>
        </group>
        <group group_id="P2">
          <title>Escitalopram + Placebo</title>
          <description>Placebo augmentation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Escitalopram + Ramelteon</title>
          <description>active augmentation</description>
        </group>
        <group group_id="B2">
          <title>Escitalopram + Placebo</title>
          <description>Placebo augmentation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.6" spread="12.4"/>
                    <measurement group_id="B2" value="42.0" spread="11.4"/>
                    <measurement group_id="B3" value="42.3" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Remitters on IDS-C30 at Week 12</title>
        <description>Remission as defined by a score of &lt;12 on the Inventory of Depressive Symptomatology, Clinician-Rated version (IDS-C30) at Week 12; minimum possible score = 0, maximum possible score = 84; higher scores indicate worse symptom severity</description>
        <time_frame>12 Weeks</time_frame>
        <population>Participants who were randomized to treatment and completed Week 12 were included in analyses</population>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram + Ramelteon</title>
            <description>active augmentation</description>
          </group>
          <group group_id="O2">
            <title>Escitalopram + Placebp</title>
            <description>control group</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Remitters on IDS-C30 at Week 12</title>
          <description>Remission as defined by a score of &lt;12 on the Inventory of Depressive Symptomatology, Clinician-Rated version (IDS-C30) at Week 12; minimum possible score = 0, maximum possible score = 84; higher scores indicate worse symptom severity</description>
          <population>Participants who were randomized to treatment and completed Week 12 were included in analyses</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Latency</title>
        <description>Number of minutes until fell asleep</description>
        <time_frame>12 weeks</time_frame>
        <population>Number of Participants with analyzable data for this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram + Ramelteon</title>
            <description>active augmentation</description>
          </group>
          <group group_id="O2">
            <title>Escitalopram + Placebo</title>
            <description>control group</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Latency</title>
          <description>Number of minutes until fell asleep</description>
          <population>Number of Participants with analyzable data for this outcome measure</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4" spread="29.1"/>
                    <measurement group_id="O2" value="15.8" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psychosocial Measures i.e. SF Health Survey, QLESQ, Social Adjustment Scale Self Report, Work and Social Adjustment Scale, Work Productivity and Activity Impairment Questionaire, and the Patients Perception of Benefits of Care.</title>
        <time_frame>12 Weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hamilton Rating Scale for Depression 17-item</title>
        <time_frame>12 Weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During 12 weeks of active treatment, plus time between consent and treatment and 2-weeks post-treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Escitalopram + Ramelteon</title>
          <description>active augmentation</description>
        </group>
        <group group_id="E2">
          <title>Escitalopram + Placebo</title>
          <description>Placebo augmentation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>swollen lymph node</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>heart pounding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>blurred vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>heartburn/indigestion/dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="10" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>stomach pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>increased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>weight gain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>stomach cramps</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>tiredness</sub_title>
                <counts group_id="E1" events="12" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>increased yawning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>sinus infection/allergy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>increased perspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle and joint aches and pains</sub_title>
                <counts group_id="E1" events="15" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>pulled back muscle</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>vivid dreams</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>sinus headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E2" events="15" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>metallic taste</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>altered taste</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>lightheadedness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>tingling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>head fullness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>fidgetiness/restlesness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="12" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>increased anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>increased urination</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>pain and discomfort in genital area</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>erectile dysfunction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>decreased libido</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>hot flashes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>sore throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr.Prabha Sunderajan- Assistant Professor</name_or_title>
      <organization>UT Southwestern Medical Center</organization>
      <phone>214-645-6964</phone>
      <email>psunderajan@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

